Aerpio Pharmaceuticals (ARPO) Misses Q2 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Aerpio Reports Third Quarter 2018 Financial Results and Provides Business Update
November 7, 2018 7:00 AM ESTTIME-2b Clinical Trial of AKB-9778 in Patients with Diabetic Retinopathy On Track
Conference Call and Webcast Today, November 7th at 8:30 a.m. EST
CINCINNATI--(BUSINESS WIRE)-- Aerpio Pharmaceuticals, Inc. (Nasdaq: ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular diseases and diabetic complications, today reported financial results for the third quarter ended September 30, 2018 and provided a business update.
Our TIME-2b clinical trial, evaluating the effect of AKB-9778, our first-in-class systemically administered Tie2... More
